ganaxolone
Selected indexed studies
- Ganaxolone. (, 2006) [PMID:35349236]
- Ganaxolone: First Approval. (Drugs, 2022) [PMID:35596878]
- Ganaxolone. (Neurotherapeutics, 2007) [PMID:17199022]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- Safety and efficacy of ganaxolone in patients with CDKL5 deficiency disorder: results from the double-blind phase of a randomised, placebo-controlled, phase 3 trial. (2022) pubmed
- Effects of ganaxolone on non-seizure outcomes in CDKL5 Deficiency Disorder: Double-blind placebo-controlled randomized trial. (2024) pubmed
- Ganaxolone: First Approval. (2022) pubmed
- Novel Medication Ganaxolone for Seizure Disorders. (2025) pubmed
- Ganaxolone. (2006) pubmed
- Ganaxolone. (2007) pubmed
- Ganaxolone in Epilepsy: Insights into a Neurosteroid-Based Therapy. (2025) pubmed
- Ganaxolone. (2022) pubmed
- Ganaxolone: A Review in Epileptic Seizures Associated with Cyclin-Dependent Kinase-Like 5 Deficiency Disorder. (2025) pubmed
- Ganaxolone: First FDA-approved Medicine for the Treatment of Seizures Associated with Cyclin-dependent Kinase-like 5 Deficiency Disorder. (2024) pubmed